FDA approves Astellas' gastric cancer therapy
The U.S. Food and Drug Administration approved Astellas' therapy to treat a type of gastric cancer, the health regulator's website showed on Friday.
Astellas nabs class-first FDA approval for CLDN18.2 gastric cancer med Vyloy
After a prior rejection, Astellas can head into the weekend celebrating a class-first FDA approval for its new gastric cancer med Vyloy. | Astellas' Vyloy won an FDA approval to treat gastric or gastroesophageal junction adenocarcinoma patients whose tumors are CLDN18.
FDA Approves First-in-Class Drug for Gastric Cancer
Zolbetuximab — now with the brand name Vyloy — is a monoclonal antibody to treat patients with advanced gastric and gastroesophageal cancers.
FDA OKs Zolbetuximab for Gastric, Gastroesophageal Cancer
FDA also approved the Ventana CLDN18 (43-14A) RxDx Assay, from Ventana Medical Systems, Inc. and Roche Diagnostics, to identify claudin 18.2–positive tumors and thus patients who may be eligible to receive zolbetuximab.
Astellas Pharma's VYLOY Receives FDA Approval For Treatment Of Advanced Gastric And GEJ Cancer
Astellas Pharma Inc. (ALPMY, ALPMY) said that the U.S. Food and Drug Administration has approved VYLOY (zolbetuximab-clzb) in
Astellas Pharma's Cancer Drug Vyloy Gets FDA Approval
Astellas Pharma's drug Vyloy was approved for treatment of advanced gastric and gastroesophageal junction cancer by the Food and Drug Administration. The pharmaceutical company said Friday the FDA approved the drug for use in combination with fluoropyrimidine-and-platinum-containing chemotherapy.
ARY News Live3h
VYLOY: Astellas’ gastric cancer therapy approved in US
Astellas Pharma today announced that the US Food and Drug Administration (FDA) has approved VYLOY (zolbetuximab-clzb) in ...
Tuko on MSN1d
Nairobi Man Diagnosed with Stage 3 Gastric Cancer Seeks Help to Raise KSh 600k for Treatment
Former Communication Authority of Kenya employee, Mathew Nyamlori who was diagnosed with stage 3 gastric cancer in 2023 seeks ...
Clinical trials confirm zolbetuximab's efficacy in gastric cancer
In Germany, around 17,000 people are diagnosed with gastric cancer every year. The disease is one of the leading causes of ...
EurekAlert!5d
New drug can extend survival in gastric cancer
In Germany, around 17,000 people are diagnosed with gastric cancer every year. The disease is one of the leading causes of ...
technologynetworks4d
Drug Extends Survival in Gastric Cancer Clinical Trial
In Germany, around 17,000 people are diagnosed with gastric cancer every year. The disease is one of the leading causes of tumour-related deaths. This is due to late diagnosis and the rapid spread ...
5 Bad Habits You May Think Are Normal Increase Your Chances Of Developing Stomach Cancer
Stomach cancer is among the deadliest cancers as it mostly shows no symptoms in the early stages and becomes almost ...
Conversion surgery for metastatic gastric cancer now viable, says expert at Prof S.M. Chandramohan oration
Conversion surgery is becoming a viable option for patients with metastatic gastric cancer who respond well to induction ...